2-Tert-butylcyclohexane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-Tert-butylcyclohexane-1-carboxylic acid
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.27
• InChiKey: FVPFFBYHXHQMCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS
  申请人：Rutgers, The State University of New Jersey

  公开号：US20180148408A1

  公开（公告）日：2018-05-31

  A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

  通过高通量筛选和引物开发的方法，识别化合物作为Keap1-Nrf2相互作用的直接抑制剂。Keap1-Nrf2相互作用的直接抑制剂比现有的间接抑制剂更具特异性，不受各种不良影响，并且是化学预防和治疗各种涉及氧化应激和/或炎症的疾病或症状的潜在药物候选者，包括但不限于癌症、糖尿病、阿尔茨海默病和帕金森病。还公开了识别新化合物以及使用所识别的新化合物或含有这些化合物的组合物来预防或治疗与Keap1-Nrf2相互作用活性相关的疾病或症状的方法。
• Benzoic Acid Derivatives of Bile Acid as FXR/TGR5 Agonists and Methods of Use Thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20170240586A1

  公开（公告）日：2017-08-24

  The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

  本发明提供了化合物I的公式：包括这些化合物的药物组合物以及使用这些化合物治疗或预防由FXR和/或TGR5介导的疾病或紊乱的方法。
• QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20120196845A1

  公开（公告）日：2012-08-02

  The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的喹啉酮-吡唑酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括上述化合物的制药组合物，以及在治疗M1受体介导的疾病中使用上述化合物和组合物的方法。
• 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150119382A1

  公开（公告）日：2015-04-30

  The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X 1 , X 1 ′, X 1 ″, R 1 , R 2 and R 3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及式（I）化合物及其溶剂合物、水合物和药学上可接受的盐，其中X1、X1'、X1"、R1、R2和R3如本文所定义，其作为FLAP调节剂有用。本发明还涉及包括式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也在本发明范围内。
• 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20150246052A1

  公开（公告）日：2015-09-03

  The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein ring A, R 1 , R 5 and R 6 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及式（I）的化合物，以及其溶剂化物、水合物和药学上可接受的盐，其中环A、R1、R5和R6如本文所定义，可用作FLAP调节剂。本发明还涉及包括式（I）的化合物的制药组合物。制备和使用式（I）的化合物的方法也在本发明的范围内。